Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders. Based on the Athersys Inc stock forecasts from 2 analysts, the average analyst target price for Athersys Inc is USD 0.50 over the next 12 months. Athersys Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Athersys Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Athersys Inc’s stock price was USD 0.21. Athersys Inc’s stock price has changed by -67.08% over the past week, -61.09% over the past month and -87.11% over the last year.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | NSD | Common Stock
Values as of 23rd May, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Last Close
USD 0.21
Change
-0.05(-17.69%)
Market Cap
USD 0.06B
1 Yr Capital Gain
-87.11%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-87.11%
Earning Growth (5 yr)
-466.96%
Average Target Price
0.50(+133.64% )
Average Analyst
Rating
Under-perform
Fundamental
Analysis
N/A
Our view of the stock is Very Bearish with a score of 0 out of 10, where 0 is very bearish and 10 very bullish
What to like
There is nothing we particularly like
What to not like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique
technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
ATHX
Athersys Inc
-87.1% 0 -87.1%
QQQ
Invesco QQQ Trust Series 1
-10.3% +0.4% -9.9%
Company Overview
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its
clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune
disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem
cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as
well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops
MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet
medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell
therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver,
kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc.
was founded in 1995 and is headquartered in Cleveland, Ohio. Address: 3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.athersys.com
Address
3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634
Fiscal Year End
December
Employees
104
Technical Indicators
Value Value
Beta -1.30 52 Week High 1.81
Short Ratio 5.80 52 Week Low 0.20
Shorted Shares 25,617,469 200 Day Moving Average 1.03
Shorted Shares Previous Month 21,269,141 50 Day Moving Average 0.61
Shares Held By Insiders 822.20% Short Percentage 6.00%
Shares Held by Institutions 23.61 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -76.29% -45.8% 9% -20.2% 5%
Dividend Return N/A 1.0% N/A 0.9% N/A
Total Return -76.29% -45.8% 9% -19.6% 5%
Trailing 12 Months
Capital Gain -87.11% -63.9% 12% -20.7% 5%
Dividend Return N/A 4.2% N/A 2.3% N/A
Total Return -87.11% -63.9% 12% -19.2% 5%
Trailing 5 Years
Capital Gain -85.24% -55.9% 29% 5.3% 8%
Dividend Return N/A 19.7% N/A 11.1% N/A
Total Return -85.24% -55.9% 29% 16.4% 8%
Average Annual (5 Year Horizon)
Capital Gain -2.19% 4.3% 44% 2.9% 27%
Dividend Return N/A 9.5% N/A 1.8% N/A
Total Return -2.19% 4.6% 44% 4.8% 26%
Risk Return Profile
Volatility (Standard
Deviation)
45.35% 58.3% 63% 32.2% 33%
Risk Adjusted Return -4.84% N/A 43% 21.1% 34%
Market Capitalization 0.06B 0.12B 29% 0.32B 19%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 8.2 N/A 16.0 N/A
pbratio 635.8 1.8 1% 1.6 0%
pcfratio -0.7 -2.5 20% -0.1 54%
pfcfratio N/A 0.6 N/A 10.1 N/A
Management Effectiveness
retequity -424.25% -57.6% 6% 0.7% 3%
retinvcap -364.79% -53.7% 3% -0.4% 4%
retass -87.78% -26.3% 4% 0.2% 2%
debtequityratio N/A 21.0% N/A 31.8% N/A
Technical Ratios
yield N/A 1.9% N/A 2.6% N/A
sratio 5.80 4.89 42% 3.11 27%
spercent 10.93% 4.8% 19% 2.9% 16%
beta -1.30 1.39 100% 1.09 99%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Downgrades Bank of America Underperform USD 1 » USD 0.25 2022-05-23
Downgraded by Bank of America Securities Buy » Neutral USD 1 » USD 0.25 2022-05-23
Target Lowered by Bank of America Securities Neutral USD 1.25 » USD 1 2022-03-16
Downgraded by Bank of America Securities Buy » Neutral USD 1.25 2021-11-19
Initiated by Bank of America Securities Buy USD 5 2020-06-25
Maintains Needham & Company LLC Buy USD 6 » USD 5 2020-05-08
Reiterated by Dawson James Buy USD 12 2020-05-06
Initiated by Citigroup Outperform USD 14 2020-04-23
Initiates Coverage On Dawson James Buy USD 11 2019-08-26
Set Price Target Maxim Group Buy USD 8 2019-01-23
Reiterates Maxim Group Buy USD 6 2018-08-08
Reiterates Maxim Group Buy USD 6 2018-07-31
Initiates Maxim Group Buy USD 6 2018-04-23
Set Price Target Maxim Group Buy USD 6 2018-03-13
Set Price Target Maxim Group Buy » Buy USD 12 » USD 6 2018-02-13
Set Price Target Maxim Group Buy » Buy USD 9 » USD 12 2017-08-07
Initiate Needham & Company LLC Buy USD 7 2017-02-07
Reiterate Maxim Group Buy USD 5 » USD 10 2016-03-11
Assigns Maxim Group USD 9 » USD 5 2015-12-22
Downgrade Piper Sandler Outperform » Neutral USD 2 » USD 1 2015-07-10
Assigns Maxim Group Buy USD 7 » USD 9 2015-01-23
Initiate Maxim Group Buy USD 3 2012-05-31

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Annual Financial (USD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Quarterly Financial (USD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ATHX:NSD (Athersys Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 24th May, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
GILD Gilead Sciences Inc -0.18 (-0.3%) USD 80.08B
REGN Regeneron Pharmaceuticals Inc +20.77 (+3.1%) USD 72.62B
VRTX Vertex Pharmaceuticals Incorpo.. +9.76 (+3.8%) USD 66.14B
MRNA Moderna Inc +1.37 (+1.0%) USD 54.19B
ALXN Alexion Pharmaceuticals Inc N/A USD 40.34B
BNTX BioNTech SE +0.22 (+0.1%) USD 39.61B
RPRX Royalty Pharma plc +0.53 (+1.3%) USD 26.64B
SGEN Seagen Inc -0.30 (-0.2%) USD 25.70B
GMAB Genmab A/S -0.25 (-0.8%) USD 20.43B
IMMU Immunomedics, Inc N/A USD 20.31B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%